A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
about
Biological markers of invasive breast cancerGenomic profiling in luminal breast cancerAdvances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized MedicineGenomic profiling of breast cancersMathematical models of the steps involved in the systemic delivery of a chemotherapeutic to a solid tumor: From circulation to survivalMolecular subtypes and imaging phenotypes of breast cancer.Signatures of breast cancer metastasis at a glanceHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenProgesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexesAssessing the clinical utility of genomic expression data across human cancers.Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensIntrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Molecular stratification of early breast cancer identifies drug targets to drive stratified medicineSelecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal CarcinomaMolecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancerA novel model to combine clinical and pathway-based transcriptomic information for the prognosis prediction of breast cancerA joint analysis of metabolomics and genetics of breast cancer.PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cellsGenes dysregulated to different extent or oppositely in estrogen receptor-positive and estrogen receptor-negative breast cancers.Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.Molecular characterization and targeted therapeutic approaches in breast cancerDefining breast cancer intrinsic subtypes by quantitative receptor expression.Development and verification of the PAM50-based Prosigna breast cancer gene signature assayCancer biomarker discovery and validation.Study design requirements for RNA sequencing-based breast cancer diagnosticsBig data and computational biology strategy for personalized prognosis.HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profilesPatterns in target-directed breast cancer research.The genomic landscape of breast cancer as a therapeutic roadmapCoINcIDE: A framework for discovery of patient subtypes across multiple datasets.Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyChromatin Regulators as a Guide for Cancer Treatment ChoiceSTAT signaling in different breast cancer sub-types.Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.
P2860
Q26781177-2B442F89-EAF1-4314-9AD2-E9ACB52C31A7Q26862681-E17063A8-E500-4030-9A8B-AA3F252B85BFQ27001994-FFB14425-F483-48DC-A4C1-FCFF80C14817Q27013013-F4120323-94E3-4150-BCEA-5F645E997FC5Q27023583-3A96F1C3-4D51-4B30-9AF5-CF8E5AFD4879Q28069885-467E7243-2418-4EAB-97FA-ECDC2BC6D5CDQ28071451-CB58D4E8-8F05-43D6-8738-3E29ECAC3A93Q28077637-B684597E-ECC3-467E-A746-3411DD6F76B0Q28306753-525F0059-7390-41B0-9D6F-9643DF85BD01Q31109151-5517C0B4-6363-4128-92AB-6A309F6B96A8Q33559365-CD49B08B-B42B-4AB4-AD52-3429BED0F8F5Q33573884-B595A9D9-3F0E-4600-86F1-3B8CFF9AC5B8Q33698446-893423B5-7C0E-480B-8CF8-0762258ED29BQ33731350-05B0E0EC-C338-4B2A-A4D8-F0A17BA06112Q33834198-212E1A95-77C1-4B0D-BEB6-5C62DCD02683Q33911898-1C9C788A-88DE-4D06-A4A2-B39972E3F22EQ34120668-08A3B06F-2BC1-4973-91F6-57BA0A31A16EQ34212421-10356FE7-BD9F-48F8-93E3-006C3DEC0034Q34296486-B47FEDB7-FC3E-43DB-BFD3-6845692E1EBEQ34433549-9AA76778-5257-4FCA-88C7-BF1CB53F122BQ34752692-0A85B4D8-90AA-491D-BABC-B6994AE59911Q34854816-BDA5A971-45CA-4ED7-BC55-080C42A85733Q34918110-5B20F74A-B08A-469D-B441-E5C94A072578Q35530143-0FA17113-F45A-4BFD-A55B-B8DAA3F8AE49Q35586697-D980C8B8-36A2-4565-ADEB-C32A59D7BA57Q35752868-46A9AB7E-C36D-435B-9483-D0CCB668A2D3Q35879887-5FA77B77-38E4-4A9A-9BD8-FDA492F72F68Q35910164-3A26D3EE-6E08-4BCE-B893-A3D0A14945AEQ36031260-EC04664F-E22C-4624-A9DA-8D767DDE8F82Q36300305-A4021BFE-43CA-434E-AC05-48559D2710B0Q36378853-0ECE98AD-FA3E-4683-B9F7-113433297817Q36383626-8C52AF67-8DF3-4FB4-964F-3967EDF270F5Q36499105-15ADADCC-0CDE-4C9D-8532-6970E4AA0E33Q36526547-995CAFBD-3789-4419-9B5C-4D74551FEC71Q36558069-9FC57900-76C3-496E-9800-B469E2C8A83FQ36667873-EE5B1AFF-7A7D-4CCE-B95B-18CC252E4F6DQ36678505-3E0F8354-891E-4036-A957-52DD29DE4EBDQ37075234-012A792D-025E-4CDC-9269-ECE5E33C29CDQ37086768-F1595CA2-2A88-44D7-B854-FC4AEBD194C6Q37094009-2263CCC8-0CDA-411F-B3FB-B3ABEBDDF2DA
P2860
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 June 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A 50-gene intrinsic subtype cl ...... nefit from adjuvant tamoxifen.
@en
A 50-gene intrinsic subtype cl ...... nefit from adjuvant tamoxifen.
@nl
type
label
A 50-gene intrinsic subtype cl ...... nefit from adjuvant tamoxifen.
@en
A 50-gene intrinsic subtype cl ...... nefit from adjuvant tamoxifen.
@nl
prefLabel
A 50-gene intrinsic subtype cl ...... nefit from adjuvant tamoxifen.
@en
A 50-gene intrinsic subtype cl ...... nefit from adjuvant tamoxifen.
@nl
P2093
P2860
P1476
A 50-gene intrinsic subtype cl ...... nefit from adjuvant tamoxifen.
@en
P2093
Dongsheng Tu
Elaine Mardis
Joel S Parker
Kathleen I Pritchard
Lois E Shepherd
Matthew J Ellis
Philip S Bernard
Samuel Leung
Shan Jiang
P2860
P304
P356
10.1158/1078-0432.CCR-12-0286
P407
P577
2012-06-18T00:00:00Z